(Q45924674)

17 December 2017

title

NF-kappaB activation is required for adaptive cardiac hypertrophy. (English)

1 reference

17 December 2017

0 references

Laura Zelarayan

1

1 reference

17 December 2017

Anke Renger

2

1 reference

17 December 2017

Claudia Noack

3

1 reference

17 December 2017

Maria-Patapia Zafiriou

4

1 reference

17 December 2017

Christina Gehrke

5

1 reference

17 December 2017

Roel van der Nagel

6

1 reference

17 December 2017

Rainer Dietz

7

1 reference

17 December 2017

Leon de Windt

8

1 reference

17 December 2017

Martin W Bergmann

9

1 reference

17 December 2017

publication date

20 July 2009

1 reference

17 December 2017

published in

Cardiovascular Research

1 reference

17 December 2017

volume

84

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

416-424

1 reference

17 December 2017

Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

The fuzzy logic of physiological cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Beta-catenin downregulation is required for adaptive cardiac remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Alterations in apoptosis regulatory factors during hypertrophy and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP237

21 January 2018

Identifiers

DOI

10.1093/CVR/CVP237

1 reference

17 December 2017

1 reference

17 December 2017